Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms

Pathogenesis of myeloproliferative neoplasms

(2015) Radek C. Skoda et al.   EXPERIMENTAL HEMATOLOGY

The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm

(2014) V. Sangkhae et al.   BLOOD

Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation

(2013) J.-P. Defour et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MPL Mutation Profile in JAK2 Mutation-negative Patients With Myeloproliferative Disorders

(2011) Wanlong Ma et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients

(2011) A Pardanani et al.   LEUKEMIA

Clinical utility of routineMPLexon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis

(2010) Elaine M. Boyd et al.   BRITISH JOURNAL OF HAEMATOLOGY

CYSTM, a novel cysteine-rich transmembrane module with a role in stress tolerance across eukaryotes

(2009) Thiago M. Venancio et al.   BIOINFORMATICS

Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor

(2009) C. Pecquet et al.   BLOOD

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

(2008) P. A. Beer et al.   BLOOD